AbCellera Biologics (ABCL)
(Real Time Quote from BATS)
$2.56 USD
-0.03 (-1.16%)
Updated Sep 23, 2024 10:42 AM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ABCL 2.56 -0.03(-1.16%)
Will ABCL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ABCL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABCL
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates
GSK (GSK) Tops Q2 Earnings and Revenue Estimates
ABCL: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Other News for ABCL
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
Tracking Baker Brothers Portfolio - Q2 2024 Update
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!